J Korean Soc Transplant.  2004 Jun;18(1):1-12.

Post-Renal Transplantation Dyslipidemia

Affiliations
  • 1Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea. curie@plaza.snu.ac.kr

Abstract

Long-term survivors in renal transplantation have been increasing, as medical care has improved in addition to development of new immunosuppressants. Therefore, cardiovascular disease, especially ischemic heart disease and chronic allograft dysfunction have become main obstacles to longer survival and better quality of life. Dyslipidemia, which is a well-known risk factor of ischemic heart disease in general population, is more common in renal transplantation patients. Moreover, dyslipidemia is suggested as a nonimmunological risk factor of chronic allograft dysfunction. Therefore, it is important to manage dyslipidemia properly to improve patient and graft survival in renal transplantation. But, specific approach, tailored to renal transplant patients is necessary in the treatment of dyslipidemia, because there are significant differences between renal transplantation patients and general population. We present here, epidemiology, mechanism, and impact of dyslipidemia on ischemic heart disease and chronic allograft dysfunction, and overall approach to dyslipidemia in renal transplantation patients, including treatment guideline.

Keyword

Dyslipidemia; Renal transplantation; Ischmic heart disease; Chronic allograft dysfunction

MeSH Terms

Allografts
Cardiovascular Diseases
Dyslipidemias*
Epidemiology
Graft Survival
Humans
Immunosuppressive Agents
Kidney Transplantation
Myocardial Ischemia
Quality of Life
Risk Factors
Survivors
Immunosuppressive Agents
Full Text Links
  • JKSTN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr